<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1729-519X</journal-id>
<journal-title><![CDATA[Revista Habanera de Ciencias Médicas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev haban cienc méd]]></abbrev-journal-title>
<issn>1729-519X</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de la Habana]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1729-519X2022000600015</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Estrategia regulatoria del desarrollo de Quimi-Hib®, vacuna conjugada semisintética contra Haemophilus influenzae tipo b]]></article-title>
<article-title xml:lang="en"><![CDATA[Regulatory strategy for development ofQuimi-Hib®, a semi-synthetic conjugate vaccine against Haemophilus influenzae type b]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez Silva]]></surname>
<given-names><![CDATA[Arlene]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hardy Rando]]></surname>
<given-names><![CDATA[Eugenio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro de Ingeniería Genética y Biotecnología  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro de Inmunología Molecular  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>21</volume>
<numero>6</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1729-519X2022000600015&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1729-519X2022000600015&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1729-519X2022000600015&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  Quimi-Hib®, una vacuna cubana obtenida por síntesis química y única en el mundo, requirió una estrategia regulatoria específica, porque no hay guía con las pautas requeridas para su producción y control.  Objetivo:  Caracterizar la estrategia regulatoria de la etapa precomercialización de Quimi-Hib® en Cuba.  Material y Métodos: Estudio descriptivo-retrospectivo de requisitos para el registro sanitario de la vacuna cubana. Se establecieron siete pasos estratégicos para abarcar los estándares reguladores vigentes y futuros, con base en opiniones de expertos para la adopción de decisiones. El punto de partida fue la guía de la OMS, aplicable a vacunas anti-Hib de origen natural.  Resultados:  La estrategia regulatoria se desarrolló a partir de las 15 recomendaciones de esta guía, 11 de ellas se extrapolaron a la vacuna cubana y cuatro no, pero se consideraron sus fundamentos para desarrollar cuatro requerimientos aplicables a la vacuna semisintética. Se adicionaron otros seis, tres a solicitud de la Autoridad Reguladora Nacional de Cuba y tres obtenidos de la literatura relevante disponible. Estos 21 requerimientos completan el paquete regulador, resultado de la estrategia desarrollada para esta vacuna y la posterior aprobación de su registro sanitario y comercialización.  Conclusiones: La estrategia regulatoria desarrollada en este trabajo permitió definir un conjunto de recomendaciones que suple la carencia de regulaciones internacionales y contribuyó a la obtención segura del registro sanitario de la vacuna Quim-Hib® que podría generalizarse a otras vacunas con características similares.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Quimi-Hib®, a Cuban vaccine obtained by chemical synthesis and unique in the world, required its own regulatory strategy because there is no guideline on the requirements for its production and control.  Objective:  To characterize the regulatory strategy of the pre-launch phase of Quimi-Hib® in Cuba.  Material and Methods: Descriptive-retrospective study of the requirements for the approval of the Cuban vaccine. Seven strategic steps were established to cover current and future regulatory standards based on expert advice for decision making. The starting point was the WHO´s guideline, which applies to anti-Hib vaccines of natural origin.  Results:  The regulatory strategy was developed based on the 15 recommendations of the aforementioned guideline, 11 of which were extrapolated to the Cuban vaccine and four of which were not, but served as the basis for the development of four requirements with similar rationale that apply to the semisynthetic vaccine. Six additional requirements were added, three of which were requested from the Cuba's National Regulatory Authority and three of which were obtained from the available relevant literature. These 21 requirements complete the regulatory package, the result of the strategy developed for this vaccine and the subsequent approval for marketing authorization and commercialization.  Conclusions: The regulatory strategy compensates for the lack of specific guidelines for synthetic Haemophilus influenzae type b vaccines and thus contributed to the approval of the first vaccine of this type. The regulatory strategy is flexible because it includes update requirements throughout the vaccine life cycle, and expert consensus was considered in its development.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Estrategia regulatoria]]></kwd>
<kwd lng="es"><![CDATA[vacunas]]></kwd>
<kwd lng="es"><![CDATA[Hib]]></kwd>
<kwd lng="es"><![CDATA[oligosacáridos sintéticos]]></kwd>
<kwd lng="es"><![CDATA[Quimi-Hib®]]></kwd>
<kwd lng="es"><![CDATA[registro sanitario]]></kwd>
<kwd lng="en"><![CDATA[regulatory strategy]]></kwd>
<kwd lng="en"><![CDATA[vaccines]]></kwd>
<kwd lng="en"><![CDATA[Hib]]></kwd>
<kwd lng="en"><![CDATA[synthetic oligosaccharides]]></kwd>
<kwd lng="en"><![CDATA[Quimi-Hib®]]></kwd>
<kwd lng="en"><![CDATA[marketing authorization]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>World Health Organization</collab>
<article-title xml:lang=""><![CDATA[Haemophilus influenzae type b (Hib) Vaccination Position Paper - September 2013]]></article-title>
<source><![CDATA[Weekly Epidemiol Record]]></source>
<year>2013</year>
<volume>88</volume>
<numero>39</numero>
<issue>39</issue>
<page-range>413-28</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Recommendations for the production and control of Haemophilus influenzae type b conjugate vaccines. Technical Report Series, No. 897 annex]]></source>
<year>2000</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vera]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Synthesis of Haemophilus influenzae type a oligosaccharides for vaccine development]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Milán ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Milán]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verez]]></surname>
<given-names><![CDATA[VG]]></given-names>
</name>
<name>
<surname><![CDATA[Roy]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Oligosacáridos derivados de ribosa-ribitol-fosfato y vacunas que los contienen]]></source>
<year>2001</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<source><![CDATA[ICH_Harmonized Tripartite Guideline. Q3C(R8) Impurities: guideline for residual solvents]]></source>
<year>2021</year>
<publisher-loc><![CDATA[Ginebra ]]></publisher-loc>
<publisher-name><![CDATA[ICH]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Guidelines for the production and quality control of synthetic peptide vaccines. Technical Report Series, No. 889 annex 1]]></source>
<year>1999</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<collab>CECMED</collab>
<source><![CDATA[Regulación M 83-15 Requisitos para el registro sanitario de productos biológicos de uso humano]]></source>
<year>2015</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[MINSAP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zarei]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Almehdar]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Redwan]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hib Vaccines: Past, Present, and Future Perspectives]]></article-title>
<source><![CDATA[J Immunol Res]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vérez Bencomo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vacuna contra el Haemophilus influenzae tipo b a partir de un antígeno sintético]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Rojas Ochoa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Vacunas. Cuba 1958-2008]]></source>
<year>2011</year>
<page-range>138-42</page-range><publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Soulis]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Global Regulatory Strategy. En: Global Pharmaceutical and Biologics Regulatory Strategy]]></source>
<year>2020</year>
<edition>2</edition>
<publisher-loc><![CDATA[EE.UU ]]></publisher-loc>
<publisher-name><![CDATA[Regulatory Affairs Professionals Society]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[History of WHO]]></source>
<year>2022</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Expert Committee on Biological Standardization]]></source>
<year>2022</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Myers]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pelletier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<collab>CRB group</collab>
<source><![CDATA[Behind every rapid response is a strong regulatory strategy]]></source>
<year>2022</year>
<publisher-loc><![CDATA[Atlanta ]]></publisher-loc>
<publisher-name><![CDATA[Crbgroup]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abdelhameed]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[GG]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Almutairi]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Duvivier]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Conrath]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A glycoconjugate of Haemophilus influenzae Type b capsular polysaccharide with tetanus toxoid protein: hydrodynamic properties mainly influenced by the carbohydrate]]></article-title>
<source><![CDATA[Sci Rep]]></source>
<year>2016</year>
<volume>6</volume>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Hardy]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reglamentación para vacunas conjugadas contra el Haemophilus influenzae de tipo b, basadas en oligosacáridos sintéticos]]></article-title>
<source><![CDATA[Rev Cubana Far]]></source>
<year>2022</year>
<volume>55</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lillo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Caro]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Proposición de estrategia regulatoria del hidrógeno para Chile]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Chile ]]></publisher-loc>
<publisher-name><![CDATA[Centro de Energía de la Pontificia Universidad Católica de Chile]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<collab>FDA</collab>
<source><![CDATA[Guidance for Industry and Review Staff. Target Product Profile - A Strategic Development Process Tool]]></source>
<year>2007</year>
<publisher-loc><![CDATA[EE UU ]]></publisher-loc>
<publisher-name><![CDATA[FDA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<collab>European Medicines Agency</collab>
<source><![CDATA[PRIME: Priority Medicines]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Amsterdam ]]></publisher-loc>
<publisher-name><![CDATA[EMA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Egües]]></surname>
<given-names><![CDATA[LI]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Galindo]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Galindo]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Resik]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Experiencia cubana en inmunización, 1962-2016]]></article-title>
<source><![CDATA[Revista Panamericana de Salud Publica]]></source>
<year>2018</year>
<volume>42</volume>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rojas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Salud y Salud Pública: Conceptualización]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Rojas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Salud y Salud Pública. Teoría y práctica]]></source>
<year>2019</year>
<page-range>4-5</page-range><publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
